289 related articles for article (PubMed ID: 19524406)
1. Influence of antipsychotics on mortality in schizophrenia: systematic review.
Weinmann S; Read J; Aderhold V
Schizophr Res; 2009 Aug; 113(1):1-11. PubMed ID: 19524406
[TBL] [Abstract][Full Text] [Related]
2. Viewpoint: do antipsychotics protect against early death? A critical view.
Whitaker R
Psychol Med; 2020 Dec; 50(16):2643-2652. PubMed ID: 33050955
[TBL] [Abstract][Full Text] [Related]
3. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.
Vermeulen J; van Rooijen G; Doedens P; Numminen E; van Tricht M; de Haan L
Psychol Med; 2017 Oct; 47(13):2217-2228. PubMed ID: 28397632
[TBL] [Abstract][Full Text] [Related]
5. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
Lancet; 2009 Aug; 374(9690):620-7. PubMed ID: 19595447
[TBL] [Abstract][Full Text] [Related]
6. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.
Smith M; Hopkins D; Peveler RC; Holt RI; Woodward M; Ismail K
Br J Psychiatry; 2008 Jun; 192(6):406-11. PubMed ID: 18515889
[TBL] [Abstract][Full Text] [Related]
7. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
8. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study.
Tiihonen J; Mittendorfer-Rutz E; Torniainen M; Alexanderson K; Tanskanen A
Am J Psychiatry; 2016 Jun; 173(6):600-6. PubMed ID: 26651392
[TBL] [Abstract][Full Text] [Related]
9. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.
De Hert M; Correll CU; Cohen D
Schizophr Res; 2010 Mar; 117(1):68-74. PubMed ID: 20060684
[TBL] [Abstract][Full Text] [Related]
10. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis.
Sørensen HJ; Jensen SO; Nielsen J
Eur Neuropsychopharmacol; 2013 Aug; 23(8):872-8. PubMed ID: 23642346
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic safety and efficacy concerns.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
[TBL] [Abstract][Full Text] [Related]
12. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.
Tiihonen J; Suokas JT; Suvisaari JM; Haukka J; Korhonen P
Arch Gen Psychiatry; 2012 May; 69(5):476-83. PubMed ID: 22566579
[TBL] [Abstract][Full Text] [Related]
13. Survival analysis of the use of first and second generation antipsychotics among patients suffering schizophrenia: A nationwide population-based cohort study.
Chen VC; Liao YT; Lai TJ; Lane HY; Shao WC; Dewey M; Lee CT; Lu ML
Schizophr Res; 2015 Dec; 169(1-3):406-411. PubMed ID: 26481616
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic treatment and mortality in schizophrenia.
Torniainen M; Mittendorfer-Rutz E; Tanskanen A; Björkenstam C; Suvisaari J; Alexanderson K; Tiihonen J
Schizophr Bull; 2015 May; 41(3):656-63. PubMed ID: 25422511
[TBL] [Abstract][Full Text] [Related]
16. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
[TBL] [Abstract][Full Text] [Related]
17. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.
Kiviniemi M; Suvisaari J; Koivumaa-Honkanen H; Häkkinen U; Isohanni M; Hakko H
Schizophr Res; 2013 Oct; 150(1):274-80. PubMed ID: 23953217
[TBL] [Abstract][Full Text] [Related]
19. Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study.
Rajkumar AP; Horsdal HT; Wimberley T; Cohen D; Mors O; Børglum AD; Gasse C
Am J Psychiatry; 2017 Jul; 174(7):686-694. PubMed ID: 28103712
[TBL] [Abstract][Full Text] [Related]
20. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
Citrome LL; Holt RI; Zachry WM; Clewell JD; Orth PA; Karagianis JL; Hoffmann VP
Ann Pharmacother; 2007 Oct; 41(10):1593-603. PubMed ID: 17785613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
